SK16993A3 - Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one - Google Patents
Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one Download PDFInfo
- Publication number
- SK16993A3 SK16993A3 SK169-93A SK16993A SK16993A3 SK 16993 A3 SK16993 A3 SK 16993A3 SK 16993 A SK16993 A SK 16993A SK 16993 A3 SK16993 A3 SK 16993A3
- Authority
- SK
- Slovakia
- Prior art keywords
- methyl
- acid
- tetrahydro
- imidazole
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Vynález sn týka spúoobu výroby 1,2,3,9-tetrahydro-9-The invention relates to a process for the production of 1,2,3,9-tetrahydro-9-
co je syntetická zlúčenina, ktorá selektívne antayonizujo vecento ry a vykazuje zaujímavé vlastnosti .9 ako an.liete t i ká v chemoterapii, ako aj pri liečbe bolestí hlavy, schizofrénie, úzkostných stavov, obezity a mánie.is a synthetic compound that selectively antayonizes the subject matter and exhibits interesting properties .9 as those in chemotherapy, as well as in the treatment of headache, schizophrenia, anxiety, obesity and mania.
Pote rajč í stav technikyThe prior art
V patentu rb ,>4ΐ·4.Ο je opísané výroba 1,2,3,9-tetrahy 'h·..)-9-,ti e t.y 1.-3- [( b-ioe ty 1- I.H- imidnzol-l-yl) nie ty l] -4dknrbnzol-i-onu reakciou karoazolonu vzorca 111In the patent rb, > 4ΐ · 4.Ο, the production of 1,2,3,9-tetrahydro-9-, thiomethyl-3- [(b-thio-1 H- imidazol-1-yl) non-phenyl] -4-benzimidazol-1-one by reaction of the caroazolone of formula 111
(III)(III)
kde Y predsta vu je aie tyl é n s kup i.nu éteho halogénme tyl skupinu, s 2-me tyl i midazolom.wherein Y is a tylene with a halogeno group, 2-methyl midazol.
V patentu ES ///1)1 je opísaná výroba 1,2,3,9-tetrabydro-9-met yl-3~ fý 2-+5 tyl--III-irnidnzo.L-1-y I.) nie tyl] - 45.1— karbazol -4-onu oxid ár. i o u korbozo lu obecného vzorca IVIn the EC patent (1) 1, the preparation of 1,2,3,9-tetrabydro-9-methyl-3-phenylethyl-3-yl-III-nitridin-1-yl-I-1 is described. tyl] - 45,1-carbazol-4-one ox. in the case of corbozol of the general formula IV
V patentu ES /393/ o p í s .;·» n ŕ v ý r o ba 1,2,3,9-tetrahydro-9- ne tyl-3 - [(2—nie- tyl -19-i. n i.dazol-1-yl) m e tyl] -4 fi-In patent ES (393), 1,2,3,9-tetrahydro-9-yl-3 - [(2-methyl-19-nitro) -19-nitro] is described. azazol-1-yl) methyl] -4-
kcie H·, a/.alebo R-, predstavuj0 o tom vodíka.or H or R-, represent 0 about that hydrogen.
V patentu ES 290993/ je opísaná výroba 1,2,3,9-tetrahy d r o - 9 - m e ty 1 - 3 - [(c - m e t y 1 -1 H - i m i d o z o 1 -1 -y 1) m e ty 1J - 4 Hkorbazol-4-onu cyklizáct ou fenylhydrazínového derivátuIn the EC patent 290993 / the production of 1,2,3,9-tetrahydro-9-methyl-3 - [(c-methyl-1H-imidozo-1-yl) methyl 1J-4 is described. Deep corazol-4-one by cyclization of the phenylhydrazine derivative
V patentu ES 2O0'.)93ó je opísaná výroba 1,2,3,9-tetrah y d r o - 9 -1 n e t y 1 - 3 - - n i e t y 1 -111 - .i ί i i d · z o 1 -1 - y 1): 11 e t y l] - 41 í k.orb -.zol-4- Snu c y k 1 izáciou anilínového derivátu obecného vzorca VilIn the EC patent 2030-193, the production of 1,2,3,9-tetrahydro-9-1-methyl-3-methyl-1-hydroxy-1-yl-1-yl is described: 11 Ethyl] -41 ketyl-4-iso-4- Snula by cyclization of an aniline derivative of the general formula
(Víl) kde X. predstavu je atóm vodíka alebo halogénu.(VII) wherein X. the notion is hydrogen or halogen.
Podstata vynálezuSUMMARY OF THE INVENTION
Predmetom vynálezu je spúsob výroby 1,2,3,9-te trati y d r o - 9 - me ty 1 - 3 - {k 2 -nie ty 1 -1! I - i m i d --j z ol --1 - y 1) me tyl j - 4 (Ίkarbazol-4-ónu obecného vzorca IIt is an object of the present invention to provide a process for the production of 1,2,3,9-th-methyl-9-methyl-3- (k-2-yl) -yl-1-carboxylic acid. I - i m i d - j z ol - 1 - y l) methyl j - 4 (Carbazol-4-one of formula I)
ktorého podstata spočíva v tom, že sa 2-[(2-metyl-lH-im.idazol-l-yl)metylj-4-il-metylindol-2-yl)kyselina maslováwhich comprises 2 - [(2-methyl-1H-imidazol-1-yl) methyl] -4-ylmethylindol-2-yl) butyric acid
(U) cyklizuje za podmienok 'Priedel-Crai' tsove j acylačnej reakcie prostredníctvom aktivácie karboxylovej skupiny pomocou kyslej(U) cyclizes under conditions of 'Priedel-Crai' ts acylation reaction through activation of the carboxyl group by acidic
I k atalýzy , v prostredí vhodného rozpúš C n dl o , načo sa oožodo verný prodiiikt obvyklým spSsob o m izoluje.Even in an environment of suitable dissolution, the rational product is isolated in a conventional manner.
A k t i v é c i. a k' a ľ· b o x y 1 o v e j 3 k u p i n y s o j: r e v á d z a p r· e v á d z a ním karboxylovej kyseliny na halogenid kyse.l iny alebo zmesný anhydrid a k y s e 1. i. n o u t r i C1 u ó r. · 3 c t o v o u j 11 e t ŕ n s u 1 f r ) n o v o u a 1 o b o t r i f 1 u o r metŕnsulfonovou, prednostne na zmesný anhydrid s ryseli.nou trifl uóroct )vou.A k t i v c i. and wherein the carboxylic acid is mixed with the carboxylic acid halide or mixed anhydride and the carboxylic acid anhydride is 1. n o u t r i C1 u ó r. 3-methanesulfonic acid, preferably to the mixed anhydride with the characteristic trifluronic acid.
Ak.) kyslého katalyzátoru sa rn^že poučiť anorganickej k y s e 1 i ny, a k > k y s e 1 i ny c h 1 o r o v o d í k. o vej, rečnej alebo Lewisovej kyseliny, ako je chlorid zinočriatý alebo chlorid hlinitý í r o v e j a .1 e b o f o o f o fluorid borit.ý,If the acid catalyst can be used, inorganic crystals may be used, and the acid catalysts may be used. oic, or Lewis acid, such as zinc chloride or aluminum chloride; and.
Prednostne sa p i užíva seliny fosforečnej.Phosphorus selins are preferably used.
a prevédza v aprotiekom organickom rozpúšťadle, o f orm. d ichl irine tan. dichloretáand converting in an aprotic organic solvent, form. d ichl irine tan. dichloretá
Reakcia 5) íi k o j e c hl o r tetrahydrof urán alebo acetoni tri.l, prednostne v acetoni trií u.Reaction 5) is a mixture of tetrahydrofuran or acetone tri, preferably in acetonitrile.
Cyklizáeia sa účelne prevádza pri tapolote v rozmedzí od -60 do -»-!?03C, prednostne pri ·.'> 3C.Cyklizáeia preferably takes the tapolote in the range of -60 to - »- !? 0 3 C, preferably at ·. '> 3 C.
Po dokončení reakcie sa požadovaný produkt konvenčným spôsob oni izoluje n prekrystal izu je z organického rozpúšťadla, prednostne me tanolu. Získa sa chemicky čistý 1,2,3,9-tetrahydro-9-met,yl-3- [( z-metyl-ld-i midazol-l-yl) m e tyl} -4K- ť knrbazol-4-on.Upon completion of the reaction, the desired product is conventionally isolated and recrystallized from an organic solvent, preferably methanol. Chemically pure 1,2,3,9-tetrahydro-9-methyl-3 - [(2-methyl-1H-imidazol-1-yl) methyl} -4K-tertbazol-4-one is obtained.
Zlúčenina obecného vzorca ii sa m3že vyrobiť reakciou 2ľie t y lén - i - (- k a r boxy-1-me ty 1 indol -z-.vl) ma sl ovej kyseliny v z o r c a V L .1. i .The compound of formula (ii) can be prepared by the reaction of 2'-thiene-i - (- k-box-1-methyl-indol-2-yl) -malic acid in zinc and in L.1. i.
s 2-metylimidazolom. Reakcia sa účelne prevádza pri teplote v rozmedzí od 100 do 2ΌΌ °C, prednostne pri 150 °C.with 2-methylimidazole. The reaction is conveniently carried out at a temperature in the range of from 100 to 2 ° C, preferably at 150 ° C.
Reakcia sa prevádza vo vysokovrúcom rozpúšťadle, ako je toluén, xylén alebo hrombenzén alebo ich zmesi, .‘'lebo bez rozpúšťadla. Prednostne sa pracuje bez rozpúšťadla.The reaction is carried out in a high boiling solvent such as toluene, xylene or thiobenzene or mixtures thereof, or without a solvent. Preferably, the process is carried out without solvent.
Po dokončení reakcie sa oožadovaný produkt konvenčnými prostriedkWizoluje a prekry 1 tniizuje z organického rozpúšťadla,ako metanolu, toluénu, diinetoxyotánu alebo metoxyetanolu, prednostne dimetoxyetánu.Upon completion of the reaction, the desired product is isolated by conventional means and recrystallized from an organic solvent such as methanol, toluene, di-ethoxyotane or methoxyethanol, preferably dimethoxyethane.
Dikarboxylová kyselina vzorcu VIII sa' získa hydrolýzou 2tne ty lén-P - (3-e toxy karbonyl-1-metyl indol-2-yl) maslové j k y s e 1 i ny v z o r c a i XThe dicarboxylic acid of formula VIII is obtained by hydrolyzing 2-thiene-β- (3-ethoxycarbonyl-1-methyl-indol-2-yl) butyric acid with zinc and X
ľúto zlúčeninu je potom možno vyrobiť reakciou etyl 1,2-d.i;n e t y 1 i n d o 1 - 3 - k a r h o xy 1 ó t u v z )r c a X (X)The lithium compound can then be produced by reacting ethyl 1,2-dihydroxy-1-3-cyclohexyl-1-ol and X (X).
(ktorý sa získa spôsobom opísaným v John E) ftyan, Michael E. Newman, J. Org. Ohern. 54, <A-bróminetylakrylovou kyselinou vzorca XI(obtained by the method of John E) phthane, Michael E. Newman, J. Org. Ohern. 54, N-bromoethylacrylic acid of formula XI
Mne or, Kov·/i n 4735, 1939) s (XI)Me or, Metal · / i n 4735, 1939) s (XI)
Brbr
OOOHOOOH
Vynález je bližšie objasnený v následujúcich príkladoch prevádzania. Tieto príklady majú výhradne ilustratívny charakter n rozsah vynálezu v žiadnom ohíade neomedzujú.The invention is illustrated by the following examples. These examples are illustrative only and do not limit the scope of the invention in any respect.
P r í klady pre v á d z ani a vynálezuExamples of the invention
-me ty lén-4 - ( 3 - e t o xyk m r bony 1.-1 - o ·-· ty 1 í nd .Ί -2-yl) masl o v k / s ·? L i. n a roztoku lítnej soli, ktorá bola vyrobená z 4,34 g (20 mmól) etyl 1,2-dioetylindol-3-korboxy.).ŕtu, vo 150 ml tetrahydrof uránu, udržiavonúh :> pri -90 JC, sa v pri e hehe 10 s pridá roztok 4,99 y (30 m.'nol) e^-brommetylakryiovej kyseliny vo 20 ml to trahydrof ur ' nu. ľ;;- plota by nemala prestúpili -50 ‘'C. Po d vochhod i nov on n i. o n o ni u pri -9 0 0C sa roztok naleje do zmesi obsahujúcej 400 >·· ír.du, 15 ml koncentrovane j kyseliny chlorovodíkovej o 2 1.) ml. e ty L oco t.átu. Po rozdelení aa fáza oddelí n vodná vrstva sa extrahuje etylacet.átom (2 x 200 •ni). Spojené organické extrakty sa vysušia síranom horečnatým a odparia. Výsledná pevná látka sa prekrystalizuje z toluénu a potom z metanolu. Získa sa 3,0 g (50 &) analyticky čistej titulnej zlúčeniny, vo forme bielej pevnej látky.-methylene-4- (3-ethoxycyclones-1-o-o-butylamino-2-yl) butter / sec. L i. on a solution of the lithium salt, which was made from 4.34 g (20 mmol) of ethyl 1,2-dioethylindole-3-carboxylate, in 150 ml of tetrahydrofuran, kept at > A solution of 4.99 g (30 mmol) of n-bromomethylacrylic acid in 20 ml of tetrahydrofuran was added over a period of 10 s. ; ;; - the fence should not exceed -50 ° C. After all, he is new. add it at the -9 0 0 C, the solution was poured into a mixture of 400> ·· ír.du, 15 ml of concentrated hydrochloric acid j 2 1) ml. e ty L oco t.át. After partitioning and phase separation, the aqueous layer was extracted with ethyl acetate (2 x 200 mL). The combined organic extracts were dried (MgSO 4) and evaporated. The resulting solid was recrystallized from toluene and then from methanol. 3.0 g (50%) of analytically pure title compound are obtained as a white solid.
Teplota tope .>enia: 138 a Ž 140 °n ^1-4045(0001^): l,4ó (t, J - 7,1, 34, -0^-01^), 2,52 - 2,71Melting point: 138 DEG-140 DEG .alpha.: 1-4045 (0001): 1.4 (t, J = 7.1, 34, -0.6% -01), 2.52-2.71
J - 1,5, III, 7,25 (m, 21i,J - 1.5, III, 7.25 (m, 21i,
P r x k 1 a d 2P r x k 1 and d 2
2--ne ty lén-4 - ( 3-karbox.y-l- ae tyl indol-2-yl) maslová kyselina2-Non-thien-4- (3-carboxy-1-methyl-indol-2-yl) butyric acid
K. suspenzii 5 ,7 g (18,9 .nmol) zlúčeniny z príkladu 1 v 15 ml metanolu a 15 ml vody sa pridá 19 g hydroxidu draselného a vzniknutá zmes sa 30 minút varí pod spätným chladičom. Potom sa zmes naleje do zmesi 200 g l'adu a 200 ml vody a okyslí 30 ml koncentrovane j kyseliny chlorovodíkovej. Produkt sa odfiltruje a suspenduje vo zpO ml toluénu. Potom sa 100 ml toluénu zo zmesi oddestiluje a po ochladení na 20 °0 a ďalšou filtráciou sa získa 4,5 g (07 Ί) analyticky čistej titulnej zlúčeniny vo forme bielej pevnej látky.To a suspension of 5.7 g (18.9 µmol) of the compound of Example 1 in 15 ml of methanol and 15 ml of water was added 19 g of potassium hydroxide, and the resulting mixture was heated under reflux for 30 minutes. The mixture is then poured into a mixture of 200 g of ice and 200 ml of water and acidified with 30 ml of concentrated hydrochloric acid. The product is filtered off and suspended in 10 ml of toluene. Thereafter, 100 mL of toluene was distilled off from the mixture and after cooling to 20 ° 0 and further filtration, 4.5 g (07 Ί) of the analytically pure title compound was obtained as a white solid.
Teplota topenia: 194 a z 195 °C 1H-NMPS(CDC1 p: 2,40 - 2,00 (m, 211, indol-C^-CH -). 3,20 3,00 (m, 211, indol-Clh-ClI;.~) , 3,77 (s, 3H, N-CH^), 5,59 (d, -C=C-H), 5,07 (d, J = 1,5, III, -0=0-11), 7,10 aromatický), 7,45 -- 7,o4 (m, 1H, aromatický),Melting point: 194-195 ° C 1 H-NMPS (CDCl 3: 2.40-2.00 (m, 2H, indole-C ^-CHCH)) 3.20 3.00 (m, 2H, indole-) CLH-CII,. ~), 3.77 (s, 3H, N-CH), 5.59 (d, -C? CH), 5.07 (d, J = 1.5, III, -0 = 0-11), 7.10 aromatic), 7.45-7.4 (m, 1H, aromatic),
7,96 - 8,05 (’ľi, l.ii, mromn tie ký ).7.96 - 8.05 (´i, liiii, mighty ones).
P r· í k 1 n d 3Example 1
- / ( P-mety 1-1 H- im idazol-l-yl] -4- (1-mety.1 i nehol-2-y 1) maslovú kyselina.- (P-Methyl-1H-imidazol-1-yl) -4- (1-methyl-indol-2-yl) -butyric acid.
Zmes 2,73 g (lOm.'nol) zlúčeniny z príkladu 2 a 2,46 g (30 -íimol) 2-;:ietyli::)idazolu sa p minúty zahrieva na lóO °C. Po ochladení na teplotu miestnosti sa zmes rozpustí v chloreformu, nanesie na chroj'iatogrní ický stĺpec oxidu kremičitého a eluuje zmesou metylénchlorid/metanol, 7θ :A mixture of 2.73 g (10 mmol) of the compound of Example 2 and 2.46 g (30 mmol) of 2-methyl-idazole was heated at 10 ° C for a minute. After cooling to room temperature, the mixture is dissolved in chloroform, applied to a silica column and eluted with methylene chloride / methanol, 7θ:
1,2 , 3,9-t e t r a-hy dr o-y-'.iin tyl-3- [(2 — me tyl-lH-imidrzol-ly 1) m e t y lj - 4 H - k n r b a z o 1 - 4 - ó n1,2,3,9-tetrahydro-y-ylamino-3 - [(2-methyl-1H-imidrzol-1-yl) methyl] -4H-pyrimidin-4-one
K suspenzii 311 mg (1 ? ml acetonitrilu sa pridá 2 fosforečnej. Reakčná zmes nej 35341)- (2,5 mmol) anhy mul) zlúčeniny 2 príkladu 3 v 10 c u.L (0,P6 kyseliny sa ochladí na 0 JC a prikvapá sa k dridu trifluoroctovej kyseliny. Po 15To a suspension of 311 mg of (1? Ml of acetonitrile was added 2 phosphoric acid. The mixture there 35341) - (2.5 mmol) of scrim anhydrides) of 2 of Example 3 in 10 uL c (0, P6 acid was cooled to 0 C and dropwise, J to the trifluoroacetic acid dride
I.I.
tT
... 9 _ minútach sa zar.es naleje do zmesi 50 y íadu a 50 ml nasýteného roztoku hyHroycnuhl i. č i tanú sodného a vzniknutá1 · zmes sa extrahuje >';ty.l.ón e hl >ridom (3 x 13 m±). opojené organické extrakt;/ sa vysni i a síranom horečnatým a odparia. Pevný zv.yšok sa prekry í tal i žuje z metanolu a tak sa získa lóO mg (552·) titulnej zlúčeniny vo forme analyticky čistej bielej pevnej látky.The mixture was poured into a mixture of 50 ml of ice and 50 ml of saturated aqueous solution for 9 minutes. No carbonate solution and the resultant one was extracted ·>'; ty.l.ón much hl> hydride (3 x 13 m ±). the combined organic extract is dried over magnesium sulphate and evaporated. The solid residue was recrystallized from methanol to give 10 mg (552%) of the title compound as an analytically pure white solid.
Teplota topenia: 227 až’2'28,5 3CMelting point: 227 C 3 až'2'28,5
1:1, H-C(2) ) ,2,13 - 4,30 (m,. 2,75 - 3,1? (m, 3Π, H-C(l) a 10 (dcl, J = 8,15, 1H,1: 1, HC (2)), 2.13-4.30 (m, 2.75-3.1? (M, 3Π, HC (1) and 10 (dcl, J = 8.15, 1H) .
N-Crl^) , ó, 85 - 7,05 (m, 21i, imidazol-H a aromatický) ,N-Cr (4), δ, 85-7.05 (m, 21i, imidazole-H and aromatic),
Ρ Λ T E N T .) V É ÍH R O K ΪΡ Λ T E N T.) OVERHEAD Ϊ
L. JpSsob výroby 1,2 , 3 , 9-t.ô trahydro-9-me tyl-3- [(2:,-ie tyl-ltl-imidazol-l-yl )me ty tj -4H-karbazol-4-ónu vzorca 1 v y i III i dL. Jp Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3 - [(2, 1-yl-1H-imidazol-1-yl) methyl] -4H-carbazole-4 -one of formula 1 or III id
a izol-l-yl) nie vzorca iiand iso-1-yl) not of formula ii
t, ý m, ž e sa 2 - [_(2 nie tyl-1Hlová kyselina — Λ— í 1 -Ίΐοΐ·,ν1 i ndo'lcharacterized in that 2 - [(2-notyl-1H-1-hylic acid) - 1 - (1 -) -, 1-indole
c jkli žuje za podmienok Priedel^Graftsovej acylačne j reakcie prostredníctvom aktívácie karboxylovej skupiny pomocou kyslej katalýzy, v prostredí vhodného rozpúšťadla, na čo sa požadovaný produkt obvyklým spúsobom izoluje.It follows the conditions of the Priedel Grafts acylation reaction by activation of the carboxyl group by acid catalysis, in a suitable solvent environment, for which the desired product is isolated in the usual manner.
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09200552A ES2043535B1 (en) | 1992-03-13 | 1992-03-13 | PROCEDURE FOR OBTAINING 1,2,3,9-TETRAHYDRO-9-METHYL-3- (2-METHYL-1H-IMIDAZOL-1-IL) METHYL * -4H-CARBAZOL-4-ONA. |
Publications (2)
Publication Number | Publication Date |
---|---|
SK16993A3 true SK16993A3 (en) | 1993-11-10 |
SK278786B6 SK278786B6 (en) | 1998-02-04 |
Family
ID=8276385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK169-93A SK278786B6 (en) | 1992-03-13 | 1993-03-08 | -1h-imidazole-1-yl)methyl|-4h-carbazol-4-one |
Country Status (15)
Country | Link |
---|---|
KR (1) | KR100277414B1 (en) |
AR (1) | AR248019A1 (en) |
AT (1) | AT402730B (en) |
CZ (1) | CZ281753B6 (en) |
EG (1) | EG20262A (en) |
ES (1) | ES2043535B1 (en) |
FI (1) | FI105098B (en) |
GR (1) | GR930100094A (en) |
HU (1) | HU210775B (en) |
IS (1) | IS1783B (en) |
NO (1) | NO300973B1 (en) |
PL (1) | PL170751B1 (en) |
PT (1) | PT101216B (en) |
RU (1) | RU2109741C1 (en) |
SK (1) | SK278786B6 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100368895B1 (en) * | 2000-03-30 | 2003-01-24 | 하나제약 주식회사 | A process for preparing 1,2,3,9-tetrahydro-9-methyl-3- [(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3502508A1 (en) * | 1984-01-25 | 1985-08-14 | Glaxo Group Ltd., London | HETEROCYCLIC COMPOUNDS |
GB8518742D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Process |
GB8518743D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Heterocyclic compounds |
GB8518741D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Process |
GB8617994D0 (en) * | 1986-07-23 | 1986-08-28 | Glaxo Group Ltd | Heterocyclic compounds |
-
1992
- 1992-03-13 ES ES09200552A patent/ES2043535B1/en not_active Expired - Fee Related
-
1993
- 1993-03-08 SK SK169-93A patent/SK278786B6/en not_active IP Right Cessation
- 1993-03-09 GR GR930100094A patent/GR930100094A/en not_active IP Right Cessation
- 1993-03-10 CZ CZ93396A patent/CZ281753B6/en not_active IP Right Cessation
- 1993-03-10 EG EG14493A patent/EG20262A/en active
- 1993-03-11 KR KR1019930003609A patent/KR100277414B1/en not_active IP Right Cessation
- 1993-03-11 NO NO930887A patent/NO300973B1/en not_active IP Right Cessation
- 1993-03-11 PT PT101216A patent/PT101216B/en not_active IP Right Cessation
- 1993-03-11 IS IS3985A patent/IS1783B/en unknown
- 1993-03-11 AR AR93324474A patent/AR248019A1/en active
- 1993-03-12 AT AT0048793A patent/AT402730B/en not_active IP Right Cessation
- 1993-03-12 HU HU9300718A patent/HU210775B/en not_active IP Right Cessation
- 1993-03-12 PL PL93298037A patent/PL170751B1/en not_active IP Right Cessation
- 1993-03-12 FI FI931104A patent/FI105098B/en not_active IP Right Cessation
- 1993-03-12 RU RU93004833/04A patent/RU2109741C1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO300973B1 (en) | 1997-08-25 |
HUT64537A (en) | 1994-01-28 |
SK278786B6 (en) | 1998-02-04 |
CZ39693A3 (en) | 1994-01-19 |
ES2043535A1 (en) | 1993-12-16 |
GR930100094A (en) | 1993-11-30 |
KR100277414B1 (en) | 2001-01-15 |
KR930019665A (en) | 1993-10-18 |
FI931104A (en) | 1993-09-14 |
PL298037A1 (en) | 1993-12-27 |
NO930887D0 (en) | 1993-03-11 |
PT101216B (en) | 1999-10-29 |
EG20262A (en) | 1998-05-31 |
IS1783B (en) | 2001-10-22 |
ES2043535B1 (en) | 1994-08-01 |
FI931104A0 (en) | 1993-03-12 |
PT101216A (en) | 1994-03-31 |
IS3985A (en) | 1993-09-14 |
FI105098B (en) | 2000-06-15 |
CZ281753B6 (en) | 1997-01-15 |
HU210775B (en) | 1995-07-28 |
ATA48793A (en) | 1996-12-15 |
HU9300718D0 (en) | 1993-05-28 |
PL170751B1 (en) | 1997-01-31 |
RU2109741C1 (en) | 1998-04-27 |
AT402730B (en) | 1997-08-25 |
NO930887L (en) | 1993-09-14 |
AR248019A1 (en) | 1995-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xie et al. | Efficient synthesis of pyrrolo [1, 2-a] quinoxalines catalyzed by a Brønsted acid through cleavage of C–C bonds | |
US5252584A (en) | Hydroxyquinolone derivatives | |
CA1094084A (en) | Halo-substituted 1-loweralkyl-5-aroylpyrrole-2-acetic acid compounds | |
EP0397060A2 (en) | Maleinimide derivatives and their use as medicines | |
JPH02142791A (en) | Pyrrolocarbazole derivatives, and their preparation and use as medicines | |
AU729386B2 (en) | 1,2-diarylindole as cox-2 inhibitors | |
CA1246563A (en) | 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl- 1h-indoles useful as analgesics | |
CA1332836C (en) | 3-oxadiazole and 3-carboxylic acid .beta.-carboline derivatives, their production and their use as drugs | |
JP2002508368A (en) | Dihydrobenzofuran | |
CA1136139A (en) | Polycyclic indole derivatives | |
Molina et al. | Fused carbazoles by tandem Aza Wittig/electrocyclic ring closure. Preparation of 6H-pyrido [4, 3-b] carbazole, 11H-pyrido [4, 3-a] carbazole and 11H-pyrido [3, 4-a] carbazole derivatives | |
JPS60158176A (en) | Substituted imidazole, manufacture and medicine | |
SK16993A3 (en) | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one | |
Nagakura et al. | Syntheses and antiinflammatory actions of 4, 5, 6, 7-tetrahydroindazole-5-carboxylic acids | |
US5973165A (en) | Process for preparing 2-oxindole | |
PL88788B1 (en) | Triazolo-isoindole and triazolo-isoquinoline derivatives and their manufacture and uses[gb1477302a] | |
PL92627B1 (en) | ||
AU7961398A (en) | Process for preparing 4-substituted-1h-indole-3-glyoxamides | |
JPS59118748A (en) | Substituted azabicycloalkane, manufacture and medicine | |
JPS60130567A (en) | 3-substituted-2-phenylindole derivative | |
Lawton et al. | Regioselectivity in the photochemical ring contraction of 4-diazopyrazolidine-3, 5-diones to give aza-β-lactams | |
US3886154A (en) | Method for the preparation of phthalazino (2,3-B) phthalazine-5(14H), 12(7H)-dione | |
HU192416B (en) | Process for preparing indole derivatives and pharmaceutical compositions containing sucg compounds | |
Strakova et al. | 1-(2-Quinoxalyl)-, 1-[3, 5-Di (trifluoromethyl) phenyl]-, 1-(2-Carboxyphenyl)-, and 1-Ethoxycarbonyl-4-oxo-4, 5, 6, 7-tetrahydroindazoles | |
JPH01265074A (en) | Novel 7-acylindole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20110308 |